Listen to Pharma Market Access Insights - from Petauri Evidence podcast

Navigating market access: Launch strategies and health economic modelling for medical devices	Pharma Market Access Insights - from Petauri Evidence	44:41
Navigating US payer evidence needs to optimise market access	Pharma Market Access Insights - from Petauri Evidence	57:34
Best practice RWE approaches to support economic modelling for HTA	Pharma Market Access Insights - from Petauri Evidence	59:53
NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas	Pharma Market Access Insights - from Petauri Evidence	62:50
De-mystifying the NHS – What you need to know about the NHS as a market for your health technology	Pharma Market Access Insights - from Petauri Evidence	56:15
NHS primary care panel – the GP Contract and Operational Planning Guidance	Pharma Market Access Insights - from Petauri Evidence	62:14
Engage NHS healthcare decision-makers with RWD	Pharma Market Access Insights - from Petauri Evidence	20:55
Market access and reimbursement in Canada – changes at CADTH	Pharma Market Access Insights - from Petauri Evidence	47:43
Rare Disease market access in the MENA and Nordic regions	Pharma Market Access Insights - from Petauri Evidence	59:10
How does funding flow in NHSE Regions?	Pharma Market Access Insights - from Petauri Evidence	60:15
NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)	Pharma Market Access Insights - from Petauri Evidence	62:06
De-mystifying health economic model classifications and structures	Pharma Market Access Insights - from Petauri Evidence	60:28
Evidence strategy for Medical Technologies and Diagnostics	Pharma Market Access Insights - from Petauri Evidence	53:24
How to set your Pharma or Medtech product up for success in the US market	Pharma Market Access Insights - from Petauri Evidence	43:06
What's happening with specialised commissioning in the NHS?	Pharma Market Access Insights - from Petauri Evidence	60:08
Integrated care in NHS Wales – what can England learn from its neighbour?	Pharma Market Access Insights - from Petauri Evidence	56:24
Market access in Italy: Reforms at AIFA	Pharma Market Access Insights - from Petauri Evidence	43:36
Unmet need in NHS primary care – How can industry best support PCN leaders?	Pharma Market Access Insights - from Petauri Evidence	60:44
Population health management: a community effort across health and life sciences	Pharma Market Access Insights - from Petauri Evidence	64:01
Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access	Pharma Market Access Insights - from Petauri Evidence	39:54
6 areas of UK health policy for Medtech to pay attention to	Pharma Market Access Insights - from Petauri Evidence	61:49
Market access in the German speaking markets	Pharma Market Access Insights - from Petauri Evidence	57:59
The role of nursing in driving digital change in the NHS	Pharma Market Access Insights - from Petauri Evidence	54:50
Market access for digital therapies and digital medicines	Pharma Market Access Insights - from Petauri Evidence	42:18
A global market access journey in cannabinoid pharmaceuticals	Pharma Market Access Insights - from Petauri Evidence	53:47
Primary Care and ICBs – what is the next step in the integration journey?	Pharma Market Access Insights - from Petauri Evidence	61:17
Data-led transformation in the NHS - partnering to optimise patient care	Pharma Market Access Insights - from Petauri Evidence	62:35
Innovating for better health – research, collaboration and innovation in the NHS	Pharma Market Access Insights - from Petauri Evidence	57:56
Healthcare, economics and society – unlocking NHS collaboration	Pharma Market Access Insights - from Petauri Evidence	59:23
Specialised Commissioning in the NHS – What do you need to know now	Pharma Market Access Insights - from Petauri Evidence	60:34
Why are we waiting? - Pressures facing the NHS and how to deliver change	Pharma Market Access Insights - from Petauri Evidence	60:47
Priority setting in primary care - NHS insights	Pharma Market Access Insights - from Petauri Evidence	59:35
Integrated Care Systems go live in the NHS - reflections after 3 weeks	Pharma Market Access Insights - from Petauri Evidence	60:21
Clinical Pharmacists – exploring the scope, capabilities, and potential of this evolving NHS role	Pharma Market Access Insights - from Petauri Evidence	60:46
Transforming systems and care pathways for an integrated NHS	Pharma Market Access Insights - from Petauri Evidence	60:47
Digital value payer communication tools: How to meet the needs of your internal stakeholders and customers	Pharma Market Access Insights - from Petauri Evidence	39:25
Population to Person: How will the NHS translate population health management into impactful, person-centred service change?	Pharma Market Access Insights - from Petauri Evidence	56:04
Planning in a volatile environment: how will the NHS reconcile its competing priorities and operational planning to meet its challenges?	Pharma Market Access Insights - from Petauri Evidence	59:25
The evolving NHS: How can Pharma and Medtech support the NHS in 2022? - NHS Insights Panel Discussion	Pharma Market Access Insights - from Petauri Evidence	62:57
Optimising the NHS – How will medicines be valued in integrated systems?	Pharma Market Access Insights - from Petauri Evidence	54:03

Navigating market access: Launch strategies and health economic modelling for medical devices

Pharma Market Access Insights - from Petauri Evidence

44:41

Navigating US payer evidence needs to optimise market access

Pharma Market Access Insights - from Petauri Evidence

57:34

Best practice RWE approaches to support economic modelling for HTA

Pharma Market Access Insights - from Petauri Evidence

59:53

NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas

Pharma Market Access Insights - from Petauri Evidence

62:50